ARIAS: Zooming in on eye-based biomarkers for Alzheimer’s

Scientists are turning to retinas as a potential screening target for early signs of Alzheimer’s, an incurable neurodegenerative disease that affects an estimated six million people in the U.S. alone.

The Atlas of Retinal Imaging in Alzheimer’s Study (ARIAS) aims to amass a reference database of retinal changes alongside traditional and exploratory outcomes that track with disease. ARIAS is recruiting participants from hospitals in Florida and Rhode Island. Redenlab are proud to partner with the PI Prof Peter Snyder to provide digital speech and language metrics over the 5 year study. We are exploring the utility and sensitivity of meaningful speech and language testing in healthy, mild cognitive impairment and early stage dementia for use in clinical trials.

To find out more about the findings, click here.

Related Post

  • Posted on 14 September, 2023
    Redenlab, a leading provider of innovative solutions in the field of pediatric and neurodevelopment communication, proudly announces that Professor Angela...
    • Posted on 11 August, 2023
      Dentatorubral-pallidoluysian atrophy (DRPLA) is a rare progressive brain disorder that can impact children and adults. In children, DRPLA can lead...
      • Posted on 27 April, 2023
        MEDIA RELEASERedenlab, a leading techbio company, proudly announces its recent feature on the highly acclaimed Huberman Podcast. The podcast episode...